ReviewCurrent opinion in virology2013
Intervention strategies for emerging viruses: use of antivirals.
Review in Current opinion in virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ribavirin for treating Crimean Congo haemorrhagic fever.The Cochrane database of systematic reviews · 2018Pooled it
- Hygiene Behaviors Associated with Influenza-Like Illness among Adults in Beijing, China: A Large, Population-Based Survey.PloS one · 2016Trial
- A Literature Review Focusing on the Antiviral Activity of [1,2,4] and [1,2,3]-triazoles.Mini reviews in medicinal chemistry · 2024Review
- Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus.Results in chemistry · 2021Review
- Severe fever with thrombocytopenia syndrome virus inhibits exogenous Type I IFN signaling pathway through its NSs invitro.PloS one · 2017Article
- Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.Viruses · 2016Review
- Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification.Nature chemical biology · 2016Article
- Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.Journal of virology · 2015Article
- Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.Reviews in medical virology · 2015Review
- Mechanism of action for respiratory syncytial virus inhibitor RSV604.Antimicrobial agents and chemotherapy · 2015Article
- Small molecules with antiviral activity against the Ebola virus.F1000Research · 2015Review
- Visualizing the replication of respiratory syncytial virus in cells and in living mice.Nature communications · 2014Article
- Nitazoxanide: a first-in-class broad-spectrum antiviral agent.Antiviral research · 2014Review
- High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses.Journal of visualized experiments : JoVE · 2014Article
- Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever.PLoS neglected tropical diseases · 2014Article
- Antiviral strategies for hepatitis E virus.Antiviral research · 2014Review
- Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.Antimicrobial agents and chemotherapy · 2014Article
- Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding.Bioorganic & medicinal chemistry letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, small molecule antiviral drugs are available for the treatment of infections with herpesviruses, HIV, HBV and HCV as well as with influenza viruses. Ribavirin, a broad-spectrum (but aspecific) antiviral, has been approved for the treatment of infections with respiratory syncytial virus, HCV and Lassa virus. Yet, for many other viruses that cause life-threatening infections [most of which are considered emerging and/or neglected] there are no drugs available. Ideally, potent and broad-spectrum (i.e., pan-genus or pan-family virus activity) antiviral drugs should be developed whereby one drug could be used for the treatment of a number of such viral infections. We here review recent evolutions in the search for inhibitors of emerging and neglected RNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.